Phase III success for Genzyme and Isis's antisense-based hypolipaemic
This article was originally published in Scrip
Executive Summary
The first Phase III trial of Isis Pharmaceuticals and Genzyme's novel antisense-based hypolipaemic mipomersen in patients with homozygous familial hypercholesterolaemia has met its primary endpoint, the companies have announced.